Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Compumedics Limited ( (AU:CMP) ).
Compumedics Limited has achieved record sales orders of $63.4 million and revenues of $51 million for FY25, with an EBITDA of $2.9 million. The company’s growth is driven by significant investments in its Somfit U.S. business and the MEG market, with a strong sales momentum in the U.S. and Asia. The company is strategically expanding its presence in the U.S. and Asia, with a focus on recurring revenue streams and innovative technologies. The launch of Somfit-D and expansion into the MEG market are expected to capture substantial market shares, positioning Compumedics for sustainable growth.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
More about Compumedics Limited
Compumedics Limited is a leading global medical device company that develops, manufactures, and commercializes diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring. The company focuses on scaling recurring revenues, strengthening global reach, and advancing differentiated technologies across sleep, neuro, and brain research.
Average Trading Volume: 84,047
Technical Sentiment Signal: Buy
Current Market Cap: A$59.59M
Learn more about CMP stock on TipRanks’ Stock Analysis page.